Shares of Celsion Corporation (NASDAQ:CLSN) gapped up before the market opened on Monday . The stock had previously closed at $1.38, but opened at $1.54. Celsion Corporation shares last traded at $1.68, with a volume of 2,036,709 shares traded.
CLSN has been the subject of a number of research analyst reports. ValuEngine raised shares of Celsion Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, May 31st. Maxim Group reiterated a “hold” rating on shares of Celsion Corporation in a research report on Thursday, June 1st. Finally, Zacks Investment Research cut shares of Celsion Corporation from a “buy” rating to a “hold” rating in a research report on Monday, June 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $24.88.
The company has a 50-day moving average price of $1.40 and a 200 day moving average price of $1.20. The firm’s market cap is $13.03 million.
A hedge fund recently raised its stake in Celsion Corporation stock. Renaissance Technologies LLC lifted its position in Celsion Corporation (NASDAQ:CLSN) by 100.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,375,147 shares of the biotechnology company’s stock after acquiring an additional 690,349 shares during the quarter. Renaissance Technologies LLC owned 2.48% of Celsion Corporation worth $397,000 at the end of the most recent reporting period. 7.47% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Celsion Corporation (CLSN) Shares Gap Up to $1.54” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.chaffeybreeze.com/2017/09/20/celsion-corporation-clsn-shares-gap-up-to-1-54.html.
Celsion Corporation Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.